AUTHOR=Nie Kun , Li Yanyi , Zhang Jiahui , Gao Yuyuan , Qiu Yihui , Gan Rong , Zhang Yuhu , Wang Lijuan 

TITLE=Distinct Bile Acid Signature in Parkinson's Disease With Mild Cognitive Impairment

JOURNAL=Frontiers in Neurology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.897867

DOI=10.3389/fneur.2022.897867

ISSN=1664-2295

ABSTRACT=<sec><title>Backgrounds</title><p>Bile acid (BA) plays a crucial role in various neurodegenerative diseases, including Parkinson's disease (PD). However, no clinical evidence supports BA's potential role in patients with PD with mild cognitive impairment (PD-MCI).</p></sec><sec><title>Objectives</title><p>This study aimed at investigating the differential BA profile between patients with PD-MCI and those with normal cognitive function (PD-NC).</p></sec><sec><title>Methods</title><p>Ultra-high performance liquid chromatography-MS/MS was applied for BA quantitation. After between-group differences of the BA profile were addressed, orthogonal projections to latent structures—discriminant analysis (OPLS-DA) and the area under the receiver-operating-characteristic curve (AUC-ROC) were implemented for further verification.</p></sec><sec><title>Results</title><p>Lower levels of chenodeoxycholic acid (CDCA), cholic acid (CA), and ursodeoxycholic acid (UDCA) were significantly associated with PD-MCI (<italic>p</italic> &lt; 0.01 for both; VIP ≈ 2.67, 1.66, and 1.26, respectively). AUC-ROC were 78.1, 74.2, and 74.5% for CDCA, CA, and UDCA, respectively.</p></sec><sec><title>Conclusion</title><p>CA, CDCA, and UDCA might be distinct BA signatures for patients with PD-MCI.</p></sec>